Of note, consistent with the result of the association between CX3CL1 and pathological stages in Figure 2, higher expression of CX3CL1 in STAD and LIHC patients was related with worse prognosis, whereas higher expression of CX3CL1 in KICH and KIRC patients was associated with better prognosis. This evidence concerns the gene CX3CL1 and gastric adenocarcinoma.